Equities analysts predict that Bausch Health Companies Inc (NYSE:BHC) will announce earnings of $0.96 per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Bausch Health Companies' earnings, with the highest EPS estimate coming in at $1.07 and the lowest estimate coming in at $0.87. Bausch Health Companies reported earnings of $1.19 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 19.3%. The business is scheduled to issue its next quarterly earnings results before the market opens on Tuesday, November 3rd.
According to Zacks, analysts expect that Bausch Health Companies will report full year earnings of $3.61 per share for the current year, with EPS estimates ranging from $3.45 to $3.80. For the next year, analysts expect that the firm will report earnings of $4.29 per share, with EPS estimates ranging from $4.00 to $4.68. Zacks Investment Research's EPS calculations are an average based on a survey of research analysts that cover Bausch Health Companies.
Bausch Health Companies (NYSE:BHC) last released its earnings results on Thursday, August 6th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.66 by ($0.20). The firm had revenue of $1.66 billion during the quarter, compared to analysts' expectations of $1.79 billion. Bausch Health Companies had a positive return on equity of 104.13% and a negative net margin of 25.19%. The company's revenue was down 22.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.07 earnings per share.
A number of research firms have commented on BHC. Bank of America raised Bausch Health Companies from an "underperform" rating to a "neutral" rating and raised their price target for the company from $16.00 to $19.00 in a report on Thursday, September 17th. BofA Securities upgraded Bausch Health Companies from an "underperform" rating to a "neutral" rating and set a $19.00 price target for the company in a research note on Thursday, September 17th. Citigroup reduced their price objective on shares of Bausch Health Companies from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. ValuEngine lowered shares of Bausch Health Companies from a "sell" rating to a "strong sell" rating in a research report on Thursday, July 2nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 price target (down from $64.00) on shares of Bausch Health Companies in a report on Monday, August 24th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company's stock. The company presently has an average rating of "Hold" and an average price target of $28.39.
In related news, insider William D. Humphries sold 5,667 shares of the company's stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $16.17, for a total transaction of $91,635.39. Following the transaction, the insider now directly owns 235,035 shares in the company, valued at approximately $3,800,515.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.14% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in BHC. FMR LLC lifted its position in shares of Bausch Health Companies by 14.4% during the first quarter. FMR LLC now owns 312,264 shares of the company's stock worth $7,704,000 after purchasing an additional 39,276 shares during the last quarter. Amundi Pioneer Asset Management Inc. increased its stake in Bausch Health Companies by 123.0% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 202,426 shares of the company's stock worth $5,000,000 after buying an additional 111,654 shares during the period. Alliancebernstein L.P. lifted its holdings in Bausch Health Companies by 67.4% during the 1st quarter. Alliancebernstein L.P. now owns 54,982 shares of the company's stock valued at $852,000 after buying an additional 22,130 shares in the last quarter. Geode Capital Management LLC boosted its position in Bausch Health Companies by 12.7% in the 1st quarter. Geode Capital Management LLC now owns 497,780 shares of the company's stock valued at $7,667,000 after buying an additional 56,204 shares during the period. Finally, Wells Fargo & Company MN grew its stake in Bausch Health Companies by 57.9% in the 1st quarter. Wells Fargo & Company MN now owns 268,735 shares of the company's stock worth $4,165,000 after acquiring an additional 98,544 shares in the last quarter. 64.46% of the stock is currently owned by institutional investors.
BHC opened at $17.11 on Friday. The stock has a market cap of $6.07 billion, a price-to-earnings ratio of -2.96, a price-to-earnings-growth ratio of 2.36 and a beta of 1.08. The company has a debt-to-equity ratio of 44.61, a quick ratio of 0.86 and a current ratio of 1.12. The firm's fifty day moving average is $16.30 and its 200 day moving average is $17.28. Bausch Health Companies has a fifty-two week low of $11.15 and a fifty-two week high of $31.97.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Further Reading: How Do Front-End Loads Impact an Investment?
Get a free copy of the Zacks research report on Bausch Health Companies (BHC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Restaurant Stocks That Still Look Tasty As the Economy Reopens
As part of our national response to the Covid-19 pandemic, many Americans considered it their patriotic, if not moral, duty to support the restaurant industry. And while many consumers were intensely focused on their small, local restaurants, the national chains were still open for business during this time.
And the reality is that the national chains are going to be the most adaptable to whatever pace of economic recovery we see. Hopes for a “V” shaped recovery have pretty much gone out the window. The new model suggests a stair-step recovery may be the best-case scenario.
The worst case scenario for the restaurant industry will be one where different regions of the country are subject to rolling lockdowns. In a business with notoriously low margins, an open/close, open/close recovery would be disastrous.
It’s one reason why I’m not sure I would be diving into restaurant stocks right now. But the same was being said of airline stocks and cruise line stocks. And sure enough, discount investors have been trying to invest in these stocks.
But as all 50 states have now re-opened in some fashion, it’s not unlikely that restaurant stocks are drawing attention from investors. We’ve put together this presentation that highlights seven restaurant stocks that you should consider looking at if you want to dive into this sector.
View the "Restaurant Stocks That Still Look Tasty As the Economy Reopens".